Mackenzie Financial Corp Sells 45,493 Shares of Medtronic PLC $MDT

Mackenzie Financial Corp decreased its position in Medtronic PLC (NYSE:MDT) by 2.3% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,949,700 shares of the medical technology company’s stock after selling 45,493 shares during the quarter. Mackenzie Financial Corp’s holdings in Medtronic were worth $185,689,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Corundum Trust Company INC bought a new stake in shares of Medtronic during the 3rd quarter valued at $27,000. Valley Wealth Managers Inc. bought a new stake in Medtronic during the third quarter worth about $29,000. Delos Wealth Advisors LLC purchased a new position in shares of Medtronic during the 2nd quarter valued at about $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medtronic in the 3rd quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC bought a new position in Medtronic during the third quarter valued at approximately $34,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Stock Performance

NYSE:MDT opened at $89.79 on Wednesday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The stock’s 50 day simple moving average is $98.45 and its two-hundred day simple moving average is $97.00. The company has a market cap of $115.28 billion, a price-to-earnings ratio of 25.01, a PEG ratio of 2.29 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same period in the previous year, the firm earned $1.38 earnings per share. Medtronic’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Analyst Ratings Changes

Several analysts have weighed in on MDT shares. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price target on shares of Medtronic in a research note on Wednesday, November 19th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Royal Bank Of Canada lifted their price target on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Citigroup initiated coverage on Medtronic in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price objective for the company. Finally, Leerink Partners restated an “outperform” rating and issued a $119.00 target price on shares of Medtronic in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire Scientia Vascular for $550 million to bolster its neurovascular access and therapeutic portfolio — a strategic tuck‑in that expands “time‑is‑brain” capabilities and complements existing neurovascular product lines. Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care
• Neutral Sentiment: Analyst coverage is active — a Benzinga deep dive summarizes 10 analyst ratings showing mixed views on MDT’s valuation and growth prospects; this keeps price target dispersion and investor debate elevated. Deep Dive Into Medtronic Stock: Analyst Perspectives (10 Ratings)
• Neutral Sentiment: Management commentary at the Barclays Healthcare Conference (transcript) reaffirmed strategy and longer‑term objectives; investors will be parsing any incremental detail on margin drivers, product cadence and the FY26 guide. Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Leadership change: Sean Haag named president of Medtronic’s ENT business — an operational move that matters for execution in ENT but is not expected to materially alter near‑term financials. Medtronic names Sean Haag president of ENT business
• Negative Sentiment: Competitive pressure from NeuroPace (NPCE) — recent coverage highlights product and reimbursement tailwinds for NeuroPace’s RNS system that could accelerate adoption in neuromodulation and pose longer‑term share/price pressure in adjacent markets. Investors view stronger competitor momentum as a headwind for Medtronic’s neuromodulation ambitions. NeuroPace’s Seizure ID and New Indication Could Expand RNS Demand
• Negative Sentiment: Macro/market volatility (rising VIX) is weighing on large‑cap medical device names, increasing downside risk from sector‑wide flows and multiple compression rather than company‑specific fundamentals. When Fear Spikes, These 5 Quiet, Overlooked Stocks Keep Delivering

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).